ASCO's technology assessment of the use of aromatase inhibitors in the adjuvant setting was last updated in 2004. ASCO's Update Committee on Aromatase Inhibitors reconvened in May 2009 to update this guideline.
No takes yet. Share an insight, caveat, or question.
Burstein et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context:
More from Journal of Oncology Practice